Alpha 2.0
Login Register
» Articles » PMID: 33370871

An IPSC Line Derived from a Human Acute Myeloid Leukemia Cell Line (HL-60-iPSC) Retains Leukemic Abnormalities and Displays Myeloid Differentiation Defects

Overview
Journal Stem Cell Res
Publisher Elsevier
Specialty Cell Biology
Date 2020 Dec 29
PMID 33370871
Citations 5
Authors
Amanda E Yamasaki
Jane N Warshaw
Beverly L Kyalwazi
Hiroko Matsui
Kristen Jepsen
Athanasia D Panopoulos
Affiliations
Soon will be listed here.
Abstract

Cancer-derived iPSCs have provided valuable insight into oncogenesis, but human cancer cells can often be difficult to reprogram, especially in cases of complex genetic abnormalities. Here we report, to our knowledge, the first successful generation of an iPSC line from a human immortalized acute myeloid leukemia (AML) cell line, the cell line HL-60. This iPSC line retains a majority of the leukemic genotype and displays defects in myeloid differentiation, thus providing a tool for modeling and studying AML.

Citing Articles

The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.

Chandra D, Alber B, Saultz J Cancers (Basel). 2024; 16(15).

PMID: 39123343 PMC: 11311077. DOI: 10.3390/cancers16152615.

Development of 3D-iNET ORION: a novel, pre-clinical, three-dimensional in vitro cell model for modeling human metastatic neuroendocrine tumor of the pancreas.

Strnadel J, Valasek M, Lin G, Lin H, Tipps A, Woo S Hum Cell. 2024; 37(5):1593-1601.

PMID: 39103560 PMC: 11341600. DOI: 10.1007/s13577-024-01113-7.

Reprogramming of Acute Myeloid Leukemia Patients Cells: Harboring Cancer Mutations Requires Targeting of AML Hierarchy.

Golubeva D, Porras D, Doyle M, Reid J, Tanasijevic B, Boyd A Stem Cells Transl Med. 2023; 12(6):334-354.

PMID: 37226319 PMC: 10267577. DOI: 10.1093/stcltm/szad022.

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation.

Guo Z, Sun L, Xia H, Tian S, Liu M, Hou J Molecules. 2022; 27(23).

PMID: 36500358 PMC: 9735585. DOI: 10.3390/molecules27238264.

Are Induced Pluripotent Stem Cells a Step towards Modeling Pediatric Leukemias?.

Bertuccio S, Leardini D, Messelodi D, Anselmi L, Manente F, Ragni F Cells. 2022; 11(3).

PMID: 35159287 PMC: 8833985. DOI: 10.3390/cells11030476.

References
1.
Gallagher R, Collins S, Trujillo J, McCredie K, AHearn M, Tsai S . Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979; 54(3):713-33. View
2.
DAntonio M, Woodruff G, Nathanson J, DAntonio-Chronowska A, Arias A, Matsui H . High-Throughput and Cost-Effective Characterization of Induced Pluripotent Stem Cells. Stem Cell Reports. 2017; 8(4):1101-1111. PMC: 5390243. DOI: 10.1016/j.stemcr.2017.03.011. View
3.
Dalton Jr W, Ahearn M, McCredie K, Freireich E, Stass S, Trujillo J . HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood. 1988; 71(1):242-7. View
4.
Panopoulos A, DAntonio M, Benaglio P, Williams R, Hashem S, Schuldt B . iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. Stem Cell Reports. 2017; 8(4):1086-1100. PMC: 5390244. DOI: 10.1016/j.stemcr.2017.03.012. View
5.
Choi K, Vodyanik M, Slukvin I . Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc. 2011; 6(3):296-313. PMC: 3066067. DOI: 10.1038/nprot.2010.184. View